Congo, The Democratic Republic of the
News Category
NanoViricides Ships NV-387 Oral Gummies to DRC for Phase II MPox Trial
NanoViricides has shipped its broad-spectrum antiviral candidate NV-387 to the Democratic Republic of Congo for a Phase II clinical trial against MPox...
NanoViricides to Initiate Phase II MPox Trial in DRC, Advancing NV-387 Against Clade I Virus
NanoViricides announced plans to start a Phase II clinical trial of its antiviral NV-387 for MPox in the Democratic Republic of Congo, aiming to addre...
Iran Conflict Disrupts Chemical Supply for DRC’s Cobalt and Copper Miners
The ongoing conflict in Iran is disrupting the supply of essential leaching chemicals for cobalt and copper miners in the Democratic Republic of Congo...
NanoViricides Advances NV-387 Toward Phase II Clinical Trials for MPox in Democratic Republic of Congo
NanoViricides reported progress on its broad-spectrum antiviral NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orph...
NanoViricides Highlights Broad-Spectrum Antiviral Candidate NV-387 Amid Ebola Outbreak
NanoViricides emphasizes the potential of its oral drug candidate NV-387 as a pandemic preparedness tool against the ongoing Bundibugyo Ebola outbreak...
NanoViricides Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak
NanoViricides announces that its broad-spectrum antiviral candidate NV-387 warrants evaluation for the Bundibugyo Ebola outbreak, given its host-targe...
CDC Expands Ebola Travel Ban to Include Green Card Holders
The CDC has extended its travel ban to include green card holders who have been to Uganda, South Sudan, or the DRC in the past 21 days to prevent Ebol...
Trident Digital Tech Launches TDTHAI Enterprise AI Platform for Asia-Pacific Markets
Trident Digital Tech Holdings Ltd. announced the launch of TDTHAI, an AI platform for enterprise deployment and digital transformation in Asia-Pacific...
NanoVirides Receives DRC Approval for Phase II Ebola Trial of NV-387 Oral Gummies
NanoVirides has obtained approval from the Democratic Republic of Congo's Pillar Committee to advance its Phase II clinical trial of NV-387 Oral Gummi...
Redwood AI Corp. Signs LOI for AI-Enabled Pathogen Surveillance Initiative in East Africa
Redwood AI Corp. has signed a non-binding letter of intent to explore a regional pathogen tracking and AI-driven outbreak intelligence initiative in C...